Early trial results hail Moderna's COVID-19 vaccine as 94.5% effective
Data also show that mRNA-1273 remains stable at 2–8°, the temperature of a standard home or medical refrigerator, for 30 days.
For the second Monday in a row, the light at the end of the tunnel - an effective vaccine against COVID-19 - burns a little brighter with Phase III interim results of Moderna's vaccine candidate demonstrating it is 94.5% effective.
The US biotechnology company's vaccine, mRNA-1273, which is going through a Phase III clinical trial (COVE), has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
The study enrolled more than 30,000 participants in the US, including communities that have historically been under-represented in clinical research and have been disproportionately affected by COVID-19. Half of the participants received a placebo, whereas the other half received two doses of the vaccine candidate.
The primary endpoint of the Phase III study (the prevention of symptomatic COVID-19 disease) is based on the analysis of COVID-19 cases confirmed and adjudicated starting 2 weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5%.
A secondary endpoint (prevention of severe COVID-19 disease) analysed severe cases of COVID-19 and included 11 severe cases in this first interim analysis. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.
Stéphane Bancel, Chief Executive Officer of Moderna, described the event as a "pivotal moment" in their effort to develop a safe and efficacious COVID-19 vaccine.
Unlike the Pfizer vaccine candidate, which has logistical challenges — it needs to be stored at about -70 °C — Moderna's vaccine remains stable at 2–8 °C, the temperature of a standard home or medical refrigerator, for 30 days. Furthermore, mRNA-1273 remains stable at -20 °C for up to 6 months, at refrigerated conditions for up to 30 days and at room temperature for up to 12 hours.
Although the trial will continue to accrue additional data relevant to safety and efficacy, the company intends to submit for an Emergency Use Authorization (EUA) with the US FDA in the coming weeks.
Pending approval, Moderna expects to have approximately 20 million doses of mRNA-1273 ready to ship in the US by the end of 2020 and remains on track to manufacture 500 million to 1 billion doses globally in 2021.
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance